{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:01:38Z","timestamp":1786132898564,"version":"build-2736575974"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1681\/asn.2014090922","type":"journal-article","created":{"date-parts":[[2014,12,26]],"date-time":"2014-12-26T21:26:51Z","timestamp":1419629211000},"page":"1238-1247","source":"Crossref","is-referenced-by-count":72,"title":["Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis"],"prefix":"10.1681","volume":"26","author":[{"given":"David M.","family":"Charytan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Barton","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20230208","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-6-20230208","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-6-20230208","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease.","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-6-20230208","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-6-20230208","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"R7-6-20230208","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"R8-6-20230208","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.V1351307","article-title":"Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.","volume":"13","author":"Paniagua","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R9-6-20230208","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2215\/CJN.00280110","article-title":"Staphylococcus aureus bacteremia and buttonhole cannulation: Long-term safety and efficacy of mupirocin prophylaxis.","volume":"5","author":"Nesrallah","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-6-20230208","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1053\/j.ajkd.2013.03.044","article-title":"The initial impact of Medicare\u2019s new prospective payment system for kidney dialysis.","volume":"62","author":"Hirth","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R12-6-20230208","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1525-139X.2009.00635.x","article-title":"Seeking safe and efficacious anemia management.","volume":"22","author":"Coyne","year":"2009","journal-title":"Semin Dial"},{"key":"R17-6-20230208","doi-asserted-by":"crossref","first-page":"906.e9","DOI":"10.1016\/j.amjmed.2012.03.011","article-title":"Changing patterns of anemia management in US hemodialysis patients.","volume":"125","author":"Freburger","year":"2012","journal-title":"Am J Med"},{"key":"R18-6-20230208","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.ajkd.2013.10.052","article-title":"Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.","volume":"63","author":"Collins","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"R19-6-20230208","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2369-14-172","article-title":"Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series.","volume":"14","author":"Thamer","year":"2013","journal-title":"BMC Nephrol"},{"key":"R20-6-20230208","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2012.76","article-title":"The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.","volume":"82","author":"Coyne","year":"2012","journal-title":"Kidney Int"},{"key":"R22-6-20230208","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000358336","article-title":"Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis.","volume":"39","author":"Susantitaphong","year":"2014","journal-title":"Am J Nephrol"},{"key":"R26-6-20230208","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1053\/j.ajkd.2013.10.006","article-title":"Commentary on \u2018The DOPPS practice monitor for U.S. dialysis care: Update on trends in anemia management 2 years into the bundle\u2019: Iron(y) abounds 2 years later.","volume":"62","author":"Weiner","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R28-6-20230208","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1053\/j.ajkd.2013.09.006","article-title":"The DOPPS practice monitor for U.S. dialysis care: Update on trends in anemia management 2 years into the bundle.","volume":"62","author":"Fuller","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R30-6-20230208","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-med-050109-142444","article-title":"Hepcidin and disorders of iron metabolism.","volume":"62","author":"Ganz","year":"2011","journal-title":"Annu Rev Med"},{"key":"R31-6-20230208","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis.","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol Rev"},{"key":"R32-6-20230208","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ki.2011.141","article-title":"Hepcidin: Clinical utility as a diagnostic tool and therapeutic target.","volume":"80","author":"Coyne","year":"2011","journal-title":"Kidney Int"},{"key":"R33-6-20230208","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism.","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"key":"R34-6-20230208","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis.","volume":"52","author":"Rozen-Zvi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R35-6-20230208","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) Study.","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R36-6-20230208","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.","volume":"19","author":"Kapoian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R38-6-20230208","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation.","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"R39-6-20230208","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1542-4758.2008.00260.x","article-title":"Determinants of C-reactive protein in chronic hemodialysis patients: Relevance of dialysis catheter utilization.","volume":"12","author":"Hung","year":"2008","journal-title":"Hemodial Int"},{"key":"R40-6-20230208","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1523-1755.2004.00480.x","article-title":"Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients.","volume":"65","author":"Canavese","year":"2004","journal-title":"Kidney Int"},{"key":"R41-6-20230208","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1681\/ASN.V7122654","article-title":"The evaluation of iron status in hemodialysis patients.","volume":"7","author":"Fishbane","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R42-6-20230208","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0272-6386(95)90649-5","article-title":"Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.","volume":"26","author":"Kalantar-Zadeh","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"R43-6-20230208","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","article-title":"The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin.","volume":"16","author":"Tessitore","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R44-6-20230208","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0609.2012.01783.x","article-title":"Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron.","volume":"89","author":"Ghoti","year":"2012","journal-title":"Eur J Haematol"},{"key":"R45-6-20230208","doi-asserted-by":"crossref","first-page":"991.e1","DOI":"10.1016\/j.amjmed.2012.01.015","article-title":"Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study.","volume":"125","author":"Rostoker","year":"2012","journal-title":"Am J Med"},{"key":"R46-6-20230208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2215\/CJN.01630408","article-title":"Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.","volume":"4","author":"Rocha","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R47-6-20230208","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.ajkd.2003.11.021","article-title":"A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome.","volume":"43","author":"Sloand","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R48-6-20230208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0272-6386(95)90151-5","article-title":"Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.","volume":"26","author":"Fishbane","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"R49-6-20230208","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1523-1755.2004.00872.x","article-title":"Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens.","volume":"66","author":"Aronoff","year":"2004","journal-title":"Kidney Int"},{"key":"R50-6-20230208","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1046\/j.1523-1755.2002.00314.x","article-title":"Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.","volume":"61","author":"Michael","year":"2002","journal-title":"Kidney Int"},{"key":"R51-6-20230208","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/ki.2008.489","article-title":"Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.","volume":"74","author":"Pizzi","year":"2008","journal-title":"Kidney Int"},{"key":"R52-6-20230208","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"R53-6-20230208","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency.","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"R56-6-20230208","first-page":"S93","article-title":"Structure, chemistry, and pharmacokinetics of intravenous iron agents.","volume":"15","author":"Danielson","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R57-6-20230208","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"R58-6-20230208","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope.","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol Pharm"},{"key":"R59-6-20230208","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/clpt.2010.80","article-title":"Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects.","volume":"88","author":"Pai","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R60-6-20230208","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.V34.3.357.357","article-title":"Characteristics of iron dextran utilization in man.","volume":"34","author":"Henderson","year":"1969","journal-title":"Blood"},{"key":"R61-6-20230208","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fphar.2014.00045","article-title":"Labile iron in cells and body fluids: Physiology, pathology, and pharmacology.","volume":"5","author":"Cabantchik","year":"2014","journal-title":"Front Pharmacol"},{"key":"R62-6-20230208","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1592\/phco.27.3.343","article-title":"Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R63-6-20230208","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","article-title":"Physicochemical properties of ferumoxytol, a new intravenous iron preparation.","volume":"39","author":"Balakrishnan","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"R64-6-20230208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/ajkd.2002.33917","article-title":"Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury.","volume":"40","author":"Zager","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R65-6-20230208","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-0031-1296218","article-title":"Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.","volume":"61","author":"Toblli","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"R66-6-20230208","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1523-1755.2004.00580.x","article-title":"The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.","volume":"65","author":"Lim","year":"2004","journal-title":"Kidney Int"},{"key":"R67-6-20230208","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ndt\/gft269","article-title":"Iron toxicity: Relevance for dialysis patients","volume":"29","author":"Fishbane","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R68-6-20230208","doi-asserted-by":"crossref","first-page":"F426","DOI":"10.1152\/ajprenal.00248.2010","article-title":"Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.","volume":"299","author":"Johnson","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"R69-6-20230208","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2369-11-16","article-title":"Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival.","volume":"11","author":"Gupta","year":"2010","journal-title":"BMC Nephrol"},{"key":"R70-6-20230208","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/ndt\/15.11.1827","article-title":"Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.","volume":"15","author":"Parkkinen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R71-6-20230208","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000094343","article-title":"Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose.","volume":"26","author":"Barton Pai","year":"2006","journal-title":"Am J Nephrol"},{"key":"R72-6-20230208","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R73-6-20230208","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1681\/ASN.V133734","article-title":"Iron administration and clinical outcomes in hemodialysis patients.","volume":"13","author":"Feldman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R74-6-20230208","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/01.ASN.0000128009.69594.BE","article-title":"Administration of parenteral iron and mortality among hemodialysis patients.","volume":"15","author":"Feldman","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R75-6-20230208","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.ajkd.2005.09.013","article-title":"Challenging the validity of the EPO index.","volume":"47","author":"Kaysen","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R76-6-20230208","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients.","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R77-6-20230208","doi-asserted-by":"crossref","first-page":"e78930","DOI":"10.1371\/journal.pone.0078930","article-title":"Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients.","volume":"8","author":"Kshirsagar","year":"2013","journal-title":"PLoS ONE"},{"key":"R78-6-20230208","doi-asserted-by":"crossref","first-page":"e50295","DOI":"10.1371\/journal.pone.0050295","article-title":"Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients.","volume":"7","author":"Kuo","year":"2012","journal-title":"PLoS ONE"},{"key":"R79-6-20230208","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1681\/ASN.V95869","article-title":"EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients.","volume":"9","author":"Hoen","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R80-6-20230208","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2012121164","article-title":"Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.","volume":"24","author":"Brookhart","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R81-6-20230208","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.","volume":"62","author":"Kliger","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R82-6-20230208","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1681\/ASN.2007101084","article-title":"Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.","volume":"19","author":"Kuo","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R83-6-20230208","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ndt\/gfi253","article-title":"Update on adverse drug events associated with parenteral iron.","volume":"21","author":"Chertow","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R84-6-20230208","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1046\/j.1523-1755.2000.00289.x","article-title":"Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy.","volume":"58","author":"Foley","year":"2000","journal-title":"Kidney Int"},{"key":"R85-6-20230208","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ndt\/gfs528","article-title":"Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, active-controlled, multi-center study.","volume":"28","author":"Charytan","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R87-6-20230208","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/ajkd.1998.v31.pm9428456","article-title":"A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.","volume":"31","author":"Auerbach","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R88-6-20230208","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1681\/ASN.2008030255","article-title":"High-molecular weight iron dextran: A wolf in sheep\u2019s clothing?","volume":"19","author":"Rodgers","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R89-6-20230208","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: Administration, efficacy, and safety.","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R90-6-20230208","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/ajkd.2003.50141","article-title":"Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (> or =250 mg) administration.","volume":"41","author":"Folkert","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R91-6-20230208","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2146\/ajhp050173","article-title":"Safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease.","volume":"63","author":"Hollands","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"R92-6-20230208","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2215\/CJN.05320513","article-title":"A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.","volume":"9","author":"Macdougall","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"R93-6-20230208","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clinthera.2013.09.028","article-title":"Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.","volume":"36","author":"Schiller","year":"2014","journal-title":"Clin Ther"},{"key":"R94-6-20230208","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial.","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201506000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:25:40Z","timestamp":1786130740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201506000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014090922","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}